Vivos Therapeutics Stock Is Moving Higher On FDA Approval For Its Sleep Apnea Device
The FDA has granted 510(k) clearance to Vivos Therapeutics Inc’s (NASDAQ:VVOS) mmRNA (modified mandibular Repositioning Nighttime Appliance) obstructive sleep apnea (OSA) device.…
Vivos Therapeutics Announces The FDA Has Granted 510(k) Market Clearance To Its mmRNA Oral Appliance for Treating Mild to Moderate Sleep Apnea
Vivos Therapeutics, Inc. (the “Company” or “Vivos”) (NASDAQ:VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for
38 Stocks Moving In Thursday’s Mid-Day Session
Gainers
Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) shares jumped 141% to $1.7950 after dropping 12% on Wednesday. Sonnet BioTherapeutics recently reported its financial results for the three months ended June 30th , 2021 and issued a business update.
34 Stocks Moving In Wednesday’s Mid-Day Session
Gainers
PharmaCyte Biotech, Inc. (NASDAQ: PMCB) shares jumped 139% to $8.18 after surging over 15% on Tuesday.
66 Biggest Movers From Yesterday
Gainers
Virpax Pharmaceuticals, Inc. (NASDAQ: VRPX) shares surged 265.5% to close at $15.35 on Tuesday after the company received a written pre-investigational new drug (pre-IND) response from the FDA regarding MMS019.
78 Biggest Movers From Friday
Gainers
PharmaCyte Biotech, Inc. (NASDAQ: PMCB) shares jumped 43.4% to close at $3.27. PharmaCyte Biotech recently reported closing of $15-million public offering.
Roth Capital Maintains Buy on Vivos Therapeutics, Lowers Price Target to $10
Roth Capital maintains Vivos Therapeutics (NASDAQ:VVOS) with a Buy and lowers the price target from $11 to $10.